0908 GMT - Innovent Biologics' near-term stock performance may depend on the approval and sales of its potential blockbuster drug Mazdutide in 1H2025, according to Deutsche Bank Research analyst Cyrus Ng in a commentary. The biotech company's share price has rebounded 14% since January 25, outperforming its peers' average of 4.9% during the same period, Ng says. However, revenue growth slowed in Q4 compared to the previous quarter, although 2024 product sales remain in line with expectations, the analyst notes. Ng maintains a buy rating and a target price of HK$49.00. Shares were last up 0.3% at HK$36.35. (tracy.qu@wsj.com)
(END) Dow Jones Newswires
February 10, 2025 04:08 ET (09:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.